Al's Comment:

 This is an experimental treatment of a new targeted drug which hits 3 targets: NTRK, ROS-1 and ALK.  Might be worth trying this trial (or trying to get it on compassionate use if you do not fit the trial) if your genomic report mentions you have 2 or 3 of these targets overexpressed.

Go to https://clinicaltrials.gov/ct2/results?term=Entrectinib+&Search=Search for the current trials with this drug.

---

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: https://www.onclive.com/conference-coverage/AACR-2016/entrectinib-achieves-high-response-rate-across-solid-tumors

---

---

---

(Everything below this line is from virtualtrials.org!)

---

Click HERE to return to brain tumor news headlines.